Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 [intedanib] Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates.
Phase of Trial: Phase I/II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Nintedanib (Primary) ; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms WoO
- 01 Sep 2016 Results predicting role of 18F-FMISO-PET (n=130) during window-of-opportunity phase published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 15 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 28 Jan 2014 Planned End Date changed from 1 Aug 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov